Ƶ

'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances

— News, features, and commentary about cancer-related issues

Ƶ MedicalToday
Onco Break over a computer rendering of a cancer cell.

The surrounding a person's experience with cancer or some other serious illness, particularly references to "battle," has the unintended effect of portraying survivors as "winners" and those who die as "losers." (NPR)

The annual cost of newly diagnosed is nearing $25 billion. (Teen Cancer America, Journal of Clinical Oncology)

A California couple has sued a fertility clinic for allegedly and then falsifying records to cover up the mistake, which the parents believe puts their young son at risk of the cancer. (CNN)

Patients living in metropolitan areas with had significantly higher rates of cancer screening. (New England Journal of Medicine)

The FDA expanded the 2021 approval of abemaciclib (Verzenio) as adjuvant treatment for early, high-risk breast cancer by removing the Ki-67 score requirement for patient selection, .

Merck announced the in castration-resistant prostate cancer after an interim analysis showed that the addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) and androgen deprivation therapy did not improve radiographic progression-free survival or overall survival (OS). In the same statement, Merck said a phase III trial of pembrolizumab plus chemotherapy did not improve OS in patients with progressive EGFR-mutant non-small cell lung cancer (NSCLC).

Merck got some good news for another phase III study that showed neoadjuvant pembrolizumab chemotherapy followed by adjuvant pembrolizumab in resectable stage II, IIIA, or IIIB NSCLC versus neoadjuvant chemotherapy.

Sobi and Sanofi announced that a (recombinant Factor VIII) in children with hemophilia A met the primary endpoint of undetectable factor VIII inhibitors.

The largest-ever study of identified new variants that could provide insight into the increased risk and poorer outcomes. (Keck School of Medicine at USC, European Urology)

Using doctors' notes, an experimental artificial intelligence (AI) system accurately predicted the for patients with cancer. (University of British Columbia, JAMA Network Open)

In another advance for AI, machine learning showed promise for that could guide development of new drugs and treatment strategies. (Pohang University of Science and Technology, Briefings in Bioinformatics)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined Ƶ in 2007.